2023 - Research.com Medicine in Sweden Leader Award
Bo Ahrén combines Internal medicine and Pathology in his studies. He conducts interdisciplinary study in the fields of Pathology and Internal medicine through his research. His study brings together the fields of Secretion and Endocrinology. Bo Ahrén integrates Insulin with Insulin resistance in his research. Insulin resistance is closely attributed to Pancreatic hormone in his research. His Pancreatic hormone study frequently draws connections to adjacent fields such as Insulin. His Diabetes mellitus study frequently intersects with other fields, such as Islet. Much of his study explores Islet relationship to Diabetes mellitus. His work often combines Type 2 diabetes and Vildagliptin studies.
His Stimulation research extends to Internal medicine, which is thematically connected. His Endocrinology study frequently draws connections to other fields, such as Secretion. Many of his studies involve connections with topics such as Islet and Insulin. Many of his studies on Islet apply to Diabetes mellitus as well. While working on this project, Bo Ahrén studies both Diabetes mellitus and Incretin. Bo Ahrén combines Incretin and Type 2 diabetes in his research. Bo Ahrén combines Type 2 diabetes and Insulin in his research. He regularly ties together related areas like Neuropeptide in his Receptor studies. His Neuropeptide study frequently draws connections between adjacent fields such as Receptor.
His Insulin resistance research is covered under the topics of Glucose homeostasis and Pancreatic hormone. His research on Pancreatic hormone often connects related topics like Insulin resistance. Bo Ahrén regularly ties together related areas like Ingestion in his Endocrinology studies. His Ingestion study frequently draws connections between related disciplines such as Internal medicine. His work on Internal medicine is being expanded to include thematically relevant topics such as Glucagon receptor. In his works, Bo Ahrén undertakes multidisciplinary study on Type 2 diabetes and Postprandial. Bo Ahrén performs multidisciplinary study on Postprandial and Type 2 diabetes in his works. His research links Glucose homeostasis with Diabetes mellitus. Insulin is closely attributed to Glucagon receptor in his work.
His study on Endocrinology is mostly dedicated to connecting different topics, such as Sitagliptin. His research on Internal medicine often connects related topics like Glimepiride. Bo Ahrén conducted interdisciplinary study in his works that combined Glimepiride and Metformin. In his study, he carries out multidisciplinary Metformin and Sitagliptin research. Bo Ahrén combines Type 2 diabetes and Liraglutide in his research. Bo Ahrén merges many fields, such as Diabetes mellitus and Exenatide, in his writings. His work on Postprandial expands to the thematically related Insulin. He integrates many fields, such as Postprandial and Type 2 diabetes, in his works. Bo Ahrén combines Glucagon and Glucagon receptor in his studies.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Interleukin-6-deficient mice develop mature-onset obesity.
Ville Wallenius;Kristina Wallenius;Bo Ahrén;Mats Rudling.
Nature Medicine (2002)
The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes.
Maria Sörhede Winzell;Bo Ahrén.
Autonomic regulation of islet hormone secretion--implications for health and disease.
Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
M Gutniak;C Orskov;J J Holst;B Ahrén.
The New England Journal of Medicine (1992)
Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
Bo Ahrén;Mona Landin-Olsson;Per Anders Jansson;Maria Svensson.
The Journal of Clinical Endocrinology and Metabolism (2004)
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
Thomas Nyström;Mark K. Gutniak;Qimin Zhang;Fan Zhang.
American Journal of Physiology-endocrinology and Metabolism (2004)
Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes.
Bo Ahrén;Ramon Gomis;Eberhard Standl;David Mills.
Diabetes Care (2004)
Islet Amyloid and Type 2 Diabetes Mellitus
Jo W.M. Höppener;Bo Ahrén;Cornelis J.M. Lips.
The New England Journal of Medicine (2000)
FOXC2 Is a Winged Helix Gene that Counteracts Obesity, Hypertriglyceridemia, and Diet-Induced Insulin Resistance
Anna Cederberg;Line M. Grønning;Bo Ahrén;Kjetil Taskén.
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.
Bo Ahrén;Erik Simonsson;Hillevi Larsson;Mona Landin-Olsson.
Diabetes Care (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: